Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following drugs acts as a microsomal enzyme inhibitor?

Cimetidine. **Explanation:** The correct answer is **Cimetidine**. This question tests the fundamental pharmacological concept of drug metabolism via the Cytochrome P450 (CYP450) enzyme system. **1. Why Cimetidine is Correct:** Cimetidine is a classic **microsomal enzyme inhibitor**. It binds to the heme iron of the CYP450 oxidase system, reducing the metabolic activity of enzymes like CYP1A2, CYP2C9, and CYP3A4. When an inhibitor is co-administered with other drugs (e.g., Warfarin or Theophylline), it decreases their metabolism, leading to increased plasma levels and potential toxicity. **2. Why the Other Options are Incorrect:** * **Rifampicin, Phenobarbitone, and Phenytoin** are all potent **microsomal enzyme inducers**. * Inducers increase the synthesis of CYP450 enzymes. This accelerates the metabolism of co-administered drugs, leading to decreased therapeutic efficacy (e.g., failure of oral contraceptives when taken with Rifampicin). **3. High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**ame (Cimetidine), **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**etilmicin (and other Azoles like Ketoconazole), **K**etoconazole. *Also: Grapefruit juice.* * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. **Key Fact:** Cimetidine is unique among H2 blockers for this effect; newer agents like Ranitidine and Famotidine have negligible effects on microsomal enzymes, making them safer regarding drug interactions.

Q: A patient is given 1000 mg of a drug that follows first-order kinetics. After 2 hours, the drug level in plasma is 500 mg. What will be the drug level in plasma after 8 hours?

62.5 mg. ### Explanation **1. Understanding the Correct Answer (B: 62.5 mg)** The drug follows **first-order kinetics**, which means a constant *fraction* of the drug is eliminated per unit of time. The time taken for the plasma concentration to reduce by 50% is the **half-life ($t_{1/2}$)**. * **Step 1 (Find $t_{1/2}$):** The initial dose is 1000 mg. After 2 hours, it becomes 500 mg. Since the concentration halved in 2 hours, the **$t_{1/2} = 2$ hours**. * **Step 2 (Calculate for 8 hours):** Total time elapsed is 8 hours. Number of half-lives ($n$) = $8 \text{ hours} / 2 \text{ hours} = 4$ half-lives. * **Step 3 (Apply the formula):** Amount remaining = $\text{Initial dose} / 2^n$ * After 2 hrs (1st $t_{1/2}$): 500 mg * After 4 hrs (2nd $t_{1/2}$): 250 mg * After 6 hrs (3rd $t_{1/2}$): 125 mg * **After 8 hrs (4th $t_{1/2}$): 62.5 mg** **2. Why Other Options are Incorrect** * **Option A (125 mg):** This is the concentration after 6 hours (3 half-lives). * **Option C (0 mg):** This would occur in **Zero-order kinetics** (where a constant *amount* is eliminated). If this were zero-order, 250 mg would be lost every hour, reaching zero at 4 hours. * **Option D (31 mg):** This is the approximate concentration after 10 hours (5 half-lives). **3. High-Yield Clinical Pearls for NEET-PG** * **First-order Kinetics:** Most drugs follow this. $t_{1/2}$ is **constant** and independent of dose. Clearance is constant. * **Zero-order Kinetics (Non-linear):** Rate of elimination is constant regardless of concentration. Examples: **WATT** (**W**arfarin/Whiskey (Ethanol), **A**spirin (high dose), **T**heophylline, **T**olbutamide, **P**henytoin). * **Steady State:** It takes **4–5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body.

Q: The duration of action of an intravenously administered drug depends on which of the following factors?

All of the above. **Explanation:** The duration of action of a drug is primarily determined by its **elimination half-life ($t_{1/2}$)**, which is the time required for the plasma concentration to reduce by 50%. The relationship is defined by the formula: $$t_{1/2} = \frac{0.693 \times V_d}{CL}$$ 1. **Volume of Distribution ($V_d$):** This represents the extent of drug distribution in the body. A high $V_d$ means the drug is sequestered in tissues, making it less available for elimination organs (liver/kidney), thereby **increasing** the duration of action. 2. **Clearance ($CL$):** This is the efficiency of the body to remove the drug. Higher clearance leads to a shorter half-life and a **shorter** duration of action. 3. **Protein Binding:** This is a crucial determinant of both $V_d$ and $CL$. Only the "free" (unbound) fraction of a drug is pharmacologically active and available for metabolism/excretion. High protein binding acts as a reservoir, slowing down the elimination process and **prolonging** the duration of action. **Why "All of the above" is correct:** Since $V_d$ and $CL$ are the primary physiological determinants of a drug's half-life, and protein binding directly influences both these parameters, all three factors collectively dictate how long a drug remains active in the body. **High-Yield Clinical Pearls for NEET-PG:** * **Redistribution:** For highly lipid-soluble drugs (e.g., **Thiopentone**), the duration of action is determined by redistribution from the brain to fat/muscles, rather than elimination half-life. * **Zero-order kinetics:** Drugs like Phenytoin, Alcohol, and Salicylates have a duration of action that increases disproportionately with dose because their clearance mechanisms saturate. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration or to completely eliminate a drug from the body.

Q: On administration of local anesthetic in an area of infection, it is not effective because of an increase in which of the following?

Cations. **Explanation:** Local anesthetics (LAs) are **weak bases** that exist in an equilibrium between two forms: the **uncharged (lipid-soluble) free base** and the **charged (water-soluble) cationic form**. **1. Why Cations is the correct answer:** For a local anesthetic to work, the uncharged base must first cross the lipid-rich neuronal membrane. Once inside the cell, it re-equilibrates into the **cationic form**, which is the active moiety that binds to and blocks the voltage-gated sodium channels. In an area of **infection/inflammation**, the tissue pH drops (becomes acidic). According to the Henderson-Hasselbalch equation, an acidic environment shifts the equilibrium toward the **cationic (ionized) form**. Because these cations are charged, they cannot cross the cell membrane to reach their site of action inside the neuron. Therefore, the anesthetic effect is significantly reduced or lost. **2. Why other options are incorrect:** * **B & C (Free base / Uncharged base):** These terms are synonymous in this context. An increase in the free base would actually *improve* the drug's ability to penetrate the nerve. In acidic infected tissues, the concentration of the free base **decreases**, not increases. **Clinical Pearls for NEET-PG:** * **Active Form:** The **cation** is the active form at the receptor (inside the cell), but the **uncharged base** is required for penetration (outside the cell). * **Alkalinization:** Adding **Sodium Bicarbonate** to local anesthetics increases the pH, shifting the equilibrium toward the uncharged base. This results in a faster onset of action and reduced pain on injection. * **Lipid Solubility:** Potency of a local anesthetic is primarily determined by its lipid solubility. * **pKa:** The closer the pKa of the drug is to the physiological pH (7.4), the faster the onset of action (e.g., Lidocaine has a lower pKa than Bupivacaine).

Q: Which of the following drugs undergoes Hoffmann elimination?

Atracurium. **Explanation:** **Atracurium** is the correct answer because it is a non-depolarizing neuromuscular blocking agent that undergoes **Hoffmann elimination**. This is a unique spontaneous molecular degradation process that occurs at physiological pH and temperature, independent of renal or hepatic function. * **Mechanism:** In Hoffmann elimination, the drug molecule breaks down into inactive metabolites (primarily **laudanosine** and monoquaternary acrylate). Because it does not rely on organ-based metabolism, Atracurium (and its isomer Cisatracurium) is the drug of choice for muscle relaxation in patients with **renal or hepatic failure**. **Analysis of Incorrect Options:** * **A. d-tubocurarine:** This is a prototype non-depolarizing blocker primarily eliminated by the kidneys (unaltered) and partly by the liver. It is known for causing significant histamine release. * **B. Acetylcholine:** This neurotransmitter is rapidly hydrolyzed by the enzyme **pseudocholinesterase** (butyrylcholinesterase) in the plasma and acetylcholinesterase at the synapse, not by spontaneous degradation. * **C. Acetazolamide:** This is a carbonic anhydrase inhibitor used as a diuretic and for glaucoma. It is excreted unchanged in the urine via active tubular secretion. **High-Yield Clinical Pearls for NEET-PG:** * **Cisatracurium:** An isomer of atracurium that also undergoes Hoffmann elimination but is more potent and produces less laudanosine, reducing the risk of seizures. * **Laudanosine Toxicity:** The major metabolite of atracurium, laudanosine, can cross the blood-brain barrier and may cause **CNS excitation or seizures** if it accumulates during prolonged infusions. * **Temperature/pH Sensitivity:** Since Hoffmann elimination is temperature and pH-dependent, the rate of drug degradation decreases in patients with **hypothermia or acidosis**, potentially prolonging the duration of neuromuscular blockade.

Q: Dose-response curves of salbutamol for bronchodilation and tachycardia are widely separated on the dose axis. This information suggests that salbutamol is:

A highly selective drug. ### Explanation **1. Why Option D is Correct: The Concept of Selectivity** Selectivity refers to the ability of a drug to act on a specific receptor or tissue at a lower dose than that required to produce effects at other sites. In this scenario, the **Dose-Response Curves (DRC)** for bronchodilation (mediated by $\beta_2$ receptors) and tachycardia (mediated by $\beta_1$ and $\beta_2$ receptors in the heart) are "widely separated." This indicates that a therapeutic effect (bronchodilation) is achieved at a much lower dose than the adverse effect (tachycardia). The greater the distance between these two curves on the dose axis, the higher the **selectivity** of the drug for the target tissue. **2. Why Other Options are Incorrect:** * **Option A (Potency):** Potency refers to the amount of drug needed to produce an effect. While Salbutamol is potent, the separation of curves describes *selectivity*, not how much drug is needed in absolute terms. * **Option B (Efficacy):** Efficacy is the maximum response ($E_{max}$) a drug can produce. The horizontal separation of curves relates to the dose (x-axis), not the maximum height of the response (y-axis). * **Option C (Toxicity):** A drug with widely separated curves for therapeutic and toxic effects is actually **safer**, as it possesses a high **Therapeutic Index**. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Selectivity is Dose-Dependent:** At higher doses, selectivity is lost. High doses of Salbutamol (e.g., via nebulization) will eventually cause $\beta_1$ stimulation, leading to tachycardia and tremors. * **Therapeutic Index (TI):** Calculated as $LD_{50} / ED_{50}$. A "widely separated" curve implies a wide TI, making the drug safer. * **Salbutamol vs. Isoprenaline:** Isoprenaline is a non-selective $\beta$-agonist; its curves for bronchodilation and tachycardia would be much closer together compared to Salbutamol.

Q: Variation in the sensitivity of response to increasing doses of a drug in different individuals can be obtained from which type of dose-response curve?

Quantal dose-response curve. **Explanation:** The core of this question lies in distinguishing between how an individual responds to a drug versus how a population responds. **1. Why Option B is Correct:** A **Quantal Dose-Response Curve (QDRC)** describes an "all-or-none" response (e.g., sleep/no sleep, death/survival) across a population. It plots the fraction of the population that manifests a specific effect at increasing doses. Because individuals have different genetic makeups and physiological states (**inter-individual variation**), they require different doses to achieve the same effect. The QDRC is the primary tool used to visualize this variation in sensitivity and to determine the **Therapeutic Index (TI)**. **2. Why Other Options are Incorrect:** * **A. Graded Dose-Response Curve:** This measures the intensity of a response in a **single individual** as the dose increases (e.g., the increase in heart rate with increasing doses of Adrenaline). It defines efficacy and potency but does not account for population-wide sensitivity variations. * **C. Potency:** This refers to the amount of drug (dose) required to produce an effect of a given intensity. It is determined by the $EC_{50}$ on a Graded curve. * **D. Efficacy:** This refers to the maximal response ($E_{max}$) a drug can produce, regardless of dose. **NEET-PG High-Yield Pearls:** * **Graded Curve:** Tells us about **Efficacy** (Maximal effect) and **Potency** ($EC_{50}$). * **Quantal Curve:** Tells us about **Selectivity**, **Safety**, and **Variability** ($ED_{50}$, $TD_{50}$, $LD_{50}$). * **Therapeutic Index (TI):** Calculated from the Quantal curve as $TI = LD_{50} / ED_{50}$. A higher TI indicates a safer drug. * **Standard Safety Margin:** Also derived from the Quantal curve: $[(LD_1 - ED_{99}) / ED_{99}] \times 100$.

Question 1

Nitroglycerin is effective when administered sublingually because it is:

Accepted Answer

Non-ionized and lipid-soluble

Answer

Ionized and lipid-soluble

Answer

Non-ionized and water-insoluble

Answer

Ionized and water-insoluble

Question 2

Which of the following drugs acts as a microsomal enzyme inhibitor?

Accepted Answer

Cimetidine

Answer

Rifampicin

Answer

Phenobarbitone

Answer

Phenytoin

Question 3

A patient is given 1000 mg of a drug that follows first-order kinetics. After 2 hours, the drug level in plasma is 500 mg. What will be the drug level in plasma after 8 hours?

Accepted Answer

62.5 mg

Answer

125 mg

Answer

0 mg

Answer

31 mg

Question 4

A partial agonist can antagonize the effects of a full agonist because it has:

Accepted Answer

High affinity but low intrinsic activity

Answer

Low affinity but high intrinsic activity

Answer

No affinity and low intrinsic activity

Answer

High affinity but no intrinsic activity

Question 5

The duration of action of an intravenously administered drug depends on which of the following factors?

Accepted Answer

All of the above

Answer

Protein binding

Answer

Clearance

Answer

Volume of distribution

Question 6

On administration of local anesthetic in an area of infection, it is not effective because of an increase in which of the following?

Accepted Answer

Cations

Answer

Free base

Answer

Uncharged base

Answer

None of the above

Question 7

Which of the following drugs undergoes Hoffmann elimination?

Accepted Answer

Atracurium

Answer

d-tubocurarine

Answer

Acetylcholine

Answer

Acetazolamide

Question 8

Dose-response curves of salbutamol for bronchodilation and tachycardia are widely separated on the dose axis. This information suggests that salbutamol is:

Accepted Answer

A highly selective drug

Answer

A highly potent cardiac stimulant

Answer

A highly efficacious bronchodilator

Answer

A highly toxic drug

Question 9

Loading dose depends on the following factors except:

Accepted Answer

Clearance of the drug

Answer

Drug concentration to be achieved

Answer

Volume of distribution

Answer

Bioavailability of drug

Question 10

Variation in the sensitivity of response to increasing doses of a drug in different individuals can be obtained from which type of dose-response curve?

Accepted Answer

Quantal dose-response curve

Answer

Graded dose-response curve

Answer

Potency

Answer

Efficacy

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?